Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM. 

Fat loss with exercise confers benefits for breast cancer biomarkers

27 Oct 2019

A year-long course of supervised exercise intervention does not appear to yield large positive effects on breast cancer biomarkers in physically inactive menopausal women, although greater fat loss with exercise does lead to more favourable biomarker trends, according to data from the Breast Cancer and Exercise Trial in Alberta (BETA).

The 24-month BETA study randomized 400 cancer-free, postmenopausal women to intervention groups prescribed moderate–vigorous aerobic exercise, 5 days/week (3 days/week supervised) for 30 minutes/session (moderate) or 60 minutes/session (high) for 12 months. All participants were required to continue with their usual diet.

After 12 months of no intervention, 24-month fasting blood samples were obtained for 84.0 percent and 82.5 percent of participants in the moderate and high groups, respectively (n=333/400).

There were no changes observed in the 0–24- or 12–24-month biomarker profiles between the high and moderate exercise groups. The high:moderate ratio of mean biomarker change ranged between 0.97 and 1.06 (p-all>0.05).

However, biomarker profiles were more favourable for participants who achieved greater than the median fat loss during the trial.

Analysis by intervention group revealed most changes in the following biomarkers high sensitivity C-reactive protein, insulin, sex hormone binding globulin (SHBG), oestradiol, although the improvements rebounded after the trial had ended. However, the only biomarkers to rebound significantly in women who lost more than the median amount of fat were SHBG and oestradiol.

The present data lend support to the hypothesis that fat loss exerts an independent effect on concentrations of breast cancer biomarkers, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM.